---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-019958"
form_type: "8-K"
ticker: "IVF"
cik: "0001417926"
company_name: "INVO Fertility, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T22:50:44.776125+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# INVO Bioscience Q1 revenue up 353% to $1.58M, net loss narrows to $1.6M

## Summary
- Revenue $1,576,286, up 353% YoY from $348,025; clinic revenue up 417% to $1.54M.
- Net loss $(1.6) million vs $(2.6) million; Adjusted EBITDA improved to $(0.5) million from $(1.7) million.
- Merger with NAYA Biosciences pending; shareholders to receive 7.3333 INVO shares per NAYA share (~18.15M shares total).
- NAYA has provided $906k in Series A Preferred Stock financing towards $5M minimum condition for merger.
- Management expects to reach break-even on current operations (ex-merger) in 2024.

## SEC filing metadata
- accession: 0001493152-24-019958
- form_type: 8-K
- ticker: IVF
- cik: 0001417926
- company_name: INVO Fertility, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1417926/000149315224019958/0001493152-24-019958-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1417926/000149315224019958/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-019958
- JSON: https://secwatch.observer/filing/0001493152-24-019958.json
- Plain text: https://secwatch.observer/filing/0001493152-24-019958.txt

## Key facts
- Earnings Releases
  INVO Fertility, Inc. reported financial results for the first quarter of 2024.
  - Period: the first quarter of 2024
  - Result: reported results
  source text: On May 15, 2024, INVO Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the period ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1417926/000149315224019958/0001493152-24-019958-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.